Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia

European Journal of Haematology

Volumn 88, Issue 1, 2012, Pages 78-86

  Levinsen, Mette ^a   Shabaneh, Diana ^a   Bohnstedt, Cathrine ^a   Harila Saari, Arja ^b   Jonsson, Olafur G ^c   Kanerva, Jukka ^d   Lindblom, Anna ^e   Lund, Bendik ^f,g   Andersen, Elisabeth W ^h   Schmiegelow, Kjeld ^a,i  

^a Rigshospitalet   (Denmark)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^g NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Childhood acute lymphoblastic leukemia; Infection; Treatment

Indexed keywords

COTRIMOXAZOLE; MERCAPTOPURINE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW SUPPRESSION; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FOLLOW UP; HUMAN; LOW DRUG DOSE; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; SEX DIFFERENCE; TREATMENT DURATION;

6-MERCAPTOPURINE; ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; METHOTREXATE; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 83655167233     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01695.x     Document Type: Article

References (38)

1. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007;CD005590.
2. Krajicek BJ, Thomas CF Jr, Limper AH. Pneumocystis pneumonia: current concepts in pathogenesis, diagnosis, and treatment. Clin Chest Med 2009;30:265-78.
3. Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978;61:35-41.
4. Pyrgos V, Shoham S, Roilides E, Walsh TJ. Pneumocystis pneumonia in children. Paediatr Respir Rev 2009;10:192-8.
5. Wheeler K, Chessells JM, Bailey CC, Richards SM. Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X. Arch Dis Child 1996;74:101-7.
6. Siegel SE, Nesbit ME, Baehner R, Sather H, Hammond GD. Pneumonia during therapy for childhood acute lymphoblastic leukemia. Am J Dis Child 1980;134:28-34.
7. Dolan G, Lilleyman JS, Richards SM. Prognostic importance of myelosuppression during maintenance treatment of lymphoblastic leukaemia. Leukaemia in Childhood Working Party of the Medical Research Council. Arch Dis Child 1989;64:1231-4.
8. Gobrecht O, Gobel U, Graubner U, Gutjahr P, Schock V, Spaar HJ, Janka-Schaub GE. [Effect of dose intensity and therapy-induced leukocytopenia in intensive therapy on the prognosis of acute lymphatic leukemia in childhood. Results in 213 patients of the COALL-85 study]. Klin Padiatr 1992;204:230-5.
9. Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999;93:2817-23.
10. Schmiegelow K, Pulczynska MK. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: should dosage be guided by white blood cell counts? Am J Pediatr Hematol Oncol 1990;12:462-7.
11. Shankar SM, Nania JJ. Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy. Paediatr Drugs 2007;9:301-9.
12. Woods WG, Daigle AE, Hutchinson RJ, Robison LL. Myelosuppression associated with co-trimoxazole as a prophylactic antibiotic in the maintenance phase of childhood acute lymphocytic leukemia. J Pediatr 1984;105:639-44.
13. Rees CA, Lennard L, Lilleyman JS, Maddocks JL. Disturbance of 6-mercaptopurine metabolism by cotrimoxazole in childhood lymphoblastic leukaemia. Cancer Chemother Pharmacol 1984;12:87-9.
14. Eys JV, Berry DM, Crist W, Doering EJ, Fernbach DJ, Pullen J, Shuster J. Effect of trimethoprim/sulfamethoxazole prophylaxis on outcome of childhood lymphocytic leukemia. A Pediatric Oncology Group Study. Cancer 1987;59:19-23.
15. Schmiegelow K, Bjork O, Glomstein A, et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol 2003;21:1332-9.
16. Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G, Mellander L, Makipernaa A, Nygaard R, Saarinen-Pihkala UM. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000;14:2267-75.
17. Mitelman F. An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S Karger, 1995.
18. Golde DW, Bersch N, Quan SG. Trimethoprim and sulphamethoxazole inhibition of haematopoiesis in vitro. Br J Haematol 1978;40:363-7.
19. Steinberg SE, Campbell CL, Rabinovitch PS, Hillman RS. The effect of trimethoprim/sulfamethoxazole on Friend erythroleukemia cells. Blood 1980;55:501-4.
20. Siegel S, Castellan NJ. Nonparametric Statistics for the Behavioral Sciences. Singapore: McGraw-Hill, 1988.
21. Andersen PK, Borgan Ø, Gill RD, Keiding N. Statistical Models Based on Counting Processes. New York, NY: Springer-Verlag, 1993.
22. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc B 1972;34:187-220.
23. Kaplan EJ, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
24. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
25. Lund B, Asberg A, Heyman M, Kanerva J, Harila-Saari A, Hasle H, Soderhall S, Jonsson OG, Lydersen S, Schmiegelow K. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer 2011;56:551-9.
26. Freifelt AG, Walsh TJ, Pizzo P. Infectious complications in the pediatric cancer patient. In: Pizzo P, Polack D, eds. Principles and Practice of Pediatric Oncology. New York, NY: Lippencott-Raven; 1997:1067-71.
27. Kaneshiro ES, Walzer PD. Comments: overview of the 5th international workshop on Pneumocystis and the 5th general meeting of the European Concerted Action on Pneumocystis Research. J Eukaryot Microbiol 1997;44:61-3.
28. Poulsen A, Demeny AK, Bang PC, Gjerum NK, Schmiegelow K. Pneumocystis carinii pneumonia during maintenance treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 2001;37:20-3.
29. Schiff D. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. J Neurooncol 1996;27:235-40.
30. Arico M, Baruchel A, Bertrand Y, et al. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29-30, 2005. Leukemia 2005;19:1145-52.
31. Hayder S, Bjork O, Nilsson B. Relapse factors during maintenance therapy of acute lymphoblastic leukemia in children. Pediatr Hematol Oncol 1992;9:21-7.
32. Lucas K, Gula MJ, Blatt J. Relapse in acute lymphoblastic leukemia as a function of white blood cell and absolute neutrophil counts during maintenance chemotherapy. Pediatr Hematol Oncol 1992;9:91-7.
33. Schmiegelow K, Pulczynska MK, Seip M. White cell count during maintenance chemotherapy for standard-risk childhood acute lymphoblastic leukemia: relation to relapse rate. Pediatr Hematol Oncol 1988;5:259-67.
34. Peeters M, Koren G, Jakubovicz D, Zipursky A. Physician compliance and relapse rates of acute lymphoblastic leukemia in children. Clin Pharmacol Ther 1988;43:228-32.
35. Schmiegelow K. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1991;8:301-12.
36. Niethammer D, Jackson RC. The effect of trimethoprim on cellular transport of methotrexate and its cytotoxicity to human lymphoblastoid cells in vitro. Br J Haematol 1976;32:273-81.
37. Rivard GE, Momparler LF, Momparler RL. Effects of trimethoprim on leukaemic cells in vitro. Br J Haematol 1981;47:221-6.
38. Bostrom BC. Effective Pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole once a day twice a week. Pediatr Blood Cancer 2009;53:239.